Olmsted Investments LLC has filed a Schedule 13G with the Securities and Exchange Commission on August 19, 2024, indicating a significant ownership stake in Allarity Therapeutics, Inc. The Utah-based investment firm reported beneficial ownership of 10,000 shares of Allarity's Series A Convertible Redeemable Preferred Stock, representing 28.6% of the class. The filing, which is a requirement for parties owning more than 5% of a company's stock, specifies that Olmsted Investments LLC has sole voting and dispositive power over the shares. The address of Allarity Therapeutics' principal executive offices is listed as 24 School St., 2nd Floor, Boston, Massachusetts, 02108. Olmsted Investments LLC has certified that the acquisition of these shares is not for the purpose of changing or influencing the control of Allarity Therapeutics, nor is it connected with any transaction that has such purpose or effect.

Olmsted Investments LLC has filed a Schedule 13G with the Securities and Exchange Commission on August 19, 2024, indicating a significant ownership stake in Allarity Therapeutics, Inc. The Utah-based investment firm reported beneficial ownership of 10,000 shares of Allarity's Series A Convertible Redeemable Preferred Stock, representing 28.6% of the class. The filing, which is a requirement for parties owning more than 5% of a company's stock, specifies that Olmsted Investments LLC has sole voting and dispositive power over the shares. The address of Allarity Therapeutics' principal executive offices is listed as 24 School St., 2nd Floor, Boston, Massachusetts, 02108. Olmsted Investments LLC has certified that the acquisition of these shares is not for the purpose of changing or influencing the control of Allarity Therapeutics, nor is it connected with any transaction that has such purpose or effect.